Gujarat Themis Biosyn QIP closes at ₹354 in 2026

QIP closure and pricing details

Gujarat Themis Biosyn has closed its qualified institutional placement (QIP) at an issue price of ₹354 per equity share. The company’s Fund-Raising Committee approved the closure on August 28, 2026. The allotment was made to eligible qualified institutional buyers (QIBs). In total, 2,11,86,440 equity shares were allotted, taking the fund raise to ₹75 crore. The QIP had opened on August 25, 2026, and closed on August 28, 2026. The pricing and closure were disclosed through company filings. The issue price of ₹354 implies a discount to the regulatory floor price that had been announced at the opening.

How the issue price compared with the floor price

The board had set the QIP floor price at ₹372.57 per equity share on August 25, 2026, with August 25 designated as the relevant date under SEBI (ICDR) regulations. The company had disclosed that it could offer a discount of up to 5% on the floor price, based on shareholder approval. The final issue price of ₹354 reflects the pricing outcome after the bidding process. This is within the stated discretion to offer a discount of up to 5% on the floor price. The company also disclosed that the trading window for designated persons was closed from August 25, 2026, and would remain closed until 48 hours after final price determination.

Allocation to QIBs and key allottees

The allotment details show a diversified set of QIB participants across mutual funds, insurance, foreign portfolio investors, and a non-banking financial company. Quant Small Cap Fund was the largest single allottee with 54,37,833 shares, representing 25.67% of the total QIP issue. Kotak Mahindra Life Insurance was allotted 28,24,859 shares, or 13.33% of the issue. Ayushmat Ltd received 24,01,130 shares, or 11.33% of the issue, and was categorised as an FPI (Corporate). Capri Global Capital was allotted 14,12,430 shares, or 6.67% of the issue. Quant Equity Top 100 Long-Short was allotted 15,00,000 shares, or 7.08% of the issue.

Share capital expansion after the allotment

Following the allotment, Gujarat Themis Biosyn reported an increase in its paid-up equity share capital. The paid-up equity share capital increased from ₹10,89,65,265 (10,89,65,265 shares) to ₹13,01,51,705 (13,01,51,705 shares). This reflects the issuance of new equity shares under the QIP. The face value of each equity share is ₹1, as referenced in the company’s QIP-related disclosures. The updated paid-up capital figure is a direct outcome of the new allotment to institutional investors.

Shareholder approval and voting outcome

The QIP fund-raising proposal had received shareholder approval through a postal ballot process. One disclosed voting outcome for the QIP resolution showed 77,845,234 votes in favour and 20,680 votes against, translating to 99.97% support. Total votes polled were reported at 77.9 million out of 109.0 million outstanding shares, representing a 71.46% participation rate. The company’s disclosures cited near-unanimous support for the QIP resolution. The broader set of shareholder approvals also covered additional proposals, including private placement of NCDs and other debt securities, as referenced in the provided data.

Market and trading context cited in the data

Separate market commentary in the provided data noted that Gujarat Themis Biosyn shares rose up to 6% intraday after shareholders approved the QIP and NCD fundraise, alongside strong quarterly results. The same report stated that Q1 profit rose 22%, without detailing absolute profit numbers. The provided data also included a bid/ask snapshot of 409.15 / 409.75. The scrip code shown in the data was 506879. These data points were presented alongside the QIP and shareholder approval updates.

Fund-raising mandate versus the ₹75 crore QIP size

In addition to the executed ₹75 crore QIP, the provided material also referred to a broader shareholder mandate. That report said the approvals gave the company a formal go-ahead to raise up to ₹1,000 crore through a QIP and up to ₹1,500 crore through non-convertible debentures (NCDs). This highlights the difference between the enabling resolution size and the specific QIP tranche that has now been completed. The closed QIP represents one completed capital-raising action under the approvals described in the data.

Upcoming board meeting for further capital proposals

The provided data also mentioned a board meeting scheduled for September 1, 2026, to consider additional fund raising. The proposal cited includes a preferential issue of equity shares and convertible warrants via private placement. The company noted that shareholder approval and regulatory clearances would be required for such an issue. This meeting is separate from the QIP closure already approved by the Fund-Raising Committee on August 28, 2026.

Key facts table

Allottee-wise summary from disclosures

Why the QIP outcome matters for investors

The QIP closure provides clarity on pricing, dilution, and the profile of participating institutions. The final issue price of ₹354 is a concrete reference point for how institutional demand translated into the final allocation, relative to the floor price of ₹372.57 and the permitted discount framework. The post-issue paid-up capital numbers quantify the equity base expansion after the allotment. The voting data shows a high approval level and a disclosed participation rate of 71.46%, which helps investors gauge shareholder engagement in capital-raising decisions. Alongside this completed ₹75 crore raise, the broader approvals cited in the data indicate the company has enabling resolutions for larger fund-raising capacity, subject to subsequent actions.

Conclusion

Gujarat Themis Biosyn has completed its QIP by issuing 2,11,86,440 shares at ₹354 and raising ₹75 crore, following shareholder approval that recorded near-unanimous support. The company has also indicated a September 1, 2026 board meeting to consider additional capital raising through equity shares and convertible warrants, subject to approvals and clearances.